Funding information
These studies were sponsored by Sanofi. In this post hoc analysis we compared glycaemic control and hypoglycaemia between insulin glargine 300 U/mL (Gla-300) and glargine 100 U/mL (Gla-100) administered once daily in people with type 2 diabetes (T2DM) from the EDITION 1 (basal plus mealtime insulin) and EDI-TION 2 (basal insulin plus oral antihyperglycaemic drugs) trials who were previously receiving twice-daily insulin. At randomization, 16 .9% and 20.0% of people in EDITION 1 and 2, respectively, were receiving twice-daily basal insulin. Glycated haemoglobin change from baseline to Month 6 was similar over 6 months with Gla-300 or Gla-100 (least squares mean difference −0.01%; 95% confidence interval [CI] −0.27 to 0.24] in EDITION 1 and 0.16%; 95% CI −0.25 to 0.57, in EDITION 2) . Participants previously receiving twice-daily insulin in EDITION 1 had a lower risk of confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycaemia with Gla-300 vs Gla-100 at night (00:00-05:59 hours), but not at any time (24 hours); in EDITION 2 the risk was reduced at night and any time (24 hours). In conclusion, Gla-300 provided similar glycaemic control with less hypoglycaemia compared with Gla-100 in people with T2DM switching from twice-daily to once-daily basal insulin.
K E Y W O R D S
basal insulin, glycaemic control, hypoglycaemia, insulin analogues, phase III study, type ; however, a substantial proportion of individuals using basal insulin still inject at least twice daily. This post hoc analysis was performed in participants who had received twice-daily injections of Gla-100 or NPH insulin at 2 different times of day during the last 7 days before randomization. Participants receiving twice-daily Gla-100 before randomization were switched to Gla-300 or remained on Gla-100 using an equivalent starting dose. For those previously receiving NPH insulin twice daily, the starting dose of Gla-300 or Gla-100 was 20% lower than the previous NPH insulin dose. The subpopulations from each study were analysed separately; participants injecting basal insulin more frequently than twice a day were excluded from the analysis.
| Outcomes
The efficacy endpoints were change in glycated haemoglobin 3 | RESULTS
| Study population
In total, 296 participants had previously received twice-daily insulin, 135/801 (16.9%) from EDITION 1, and 161/804 (20.0%) from EDI-TION 2. Baseline characteristics were similar in both treatment groups overall and within each study for these participants (File S1
Results; Table S1 ).
| Glycaemic control
Overall, a greater decrease in HbA1c from baseline to Month 6 for participants previously receiving twice-daily insulin was observed in EDITION 1 than EDITION 2; however, similar improvements were observed for Gla-300 and Gla-100 ( Figure 1 ). The least squares with those previously reported for the overall study population, 12, 13 and with those observed in participants previously receiving oncedaily dosing ( Figure S1 , File S1). HbA1c over 6 months in participants previously treated with twice-daily basal insulin in A, the EDITION 1 study and B, the EDITION 2 study (modified intention-to-treat population). Abbreviation: s.e., standard error Similar changes in pre-breakfast SMPG and 8-point SMPG profiles were found between Gla-300 and Gla-100 in both studies (File S1 Results; Table S2 ). These changes were consistent with those observed in the overall population. 12, 13 Low variability (~20%-30%) in 8-point SMPG profiles was consistently observed across all study visits for both treatment groups in EDITION 1 and 2 (File S1, Table S2 ).
| Insulin dose
Mean daily basal insulin dose increased from baseline to Month 6 in both treatment groups, with the greatest increase during the initial 12 weeks of treatment and a higher dose increase observed with Gla-300 (File S1, Table S3 ). A greater relative difference in insulin dose between treatment groups was observed in EDITION 1 than EDITION 2 (13.2% vs 8.6%).
| Hypoglycaemia
The risk of confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe nocturnal hypoglycaemia was lower with Gla-300 than Gla-100 in both EDITION 1 and 2 ( Figure 2A and Table S4 , File S1). In EDITION 2, participants previously receiving twice-daily insulin also had a reduced risk of confirmed or severe hypoglycaemia at any time of day (24 hours) with Gla-300 vs Gla-100, regardless of the glycaemic threshold.
Annualized rates of confirmed or severe hypoglycaemia in participants previously receiving twice-daily insulin were similar for Gla-300
and Gla-100 in EDITION 1 ( Figure 2B and Table S5 , File S1). In EDI-TION 2, the annualized rate of nocturnal confirmed or severe hypoglycaemia was lower with Gla-300 vs Gla-100 at the ≤3.9 mmol/L (≤70 mg/dL) threshold, and similar with Gla-100 at the stricter threshold (<3.0 mmol/L [<54 mg/dL]). No significant between-group differences were noted for annualized rates of confirmed or severe hypoglycaemia at any time of day (24 hours).
Incidence and annualized rates of hypoglycaemia in participants previously receiving twice-daily insulin were generally consistent with those previously receiving once-daily insulin ( Figures S2 and S3 , File S1) and the overall population. 12, 13 For severe hypoglycaemia, the incidence and annualized rates in participants previously receiving twice-daily insulin was low and similar between treatment groups (Tables S4 and S5 , File S1).
Gla-300
Gla-100 Gla-300 Gla-100 with Gla-300 vs Gla-100 at night (00:00-05:59 hours), while in EDI-TION 2, the risk was reduced both at night and at any time of day (24 hours).
Interestingly, participants in the Gla-100 subgroup experienced a reduction in HbA1c, despite several having already received Gla-100
prior to the study. This may reflect the rigorous titration algorithm used in these treat-to-target studies. 12, 13 It is also possible that participants previously on a twice-daily regimen had previously found the management regimen complicated and had difficulty with self-titration; hence the improvement when switching to once-daily Gla-100.
While 16.9% and 20.0% of participants in EDITION 1 and EDITION 2, respectively, were previously receiving twice-daily basal insulin, the possible reasons for this may differ. In EDITION 1, the mean daily basal insulin dose in those previously on a twice-daily regimen was >80 U at baseline. As the maximum dose delivered by injection devices used for Gla-100 and NPH insulin is 60 to 80 U/d, participants may have chosen a twice-daily regimen to avoid injecting twice at the same time. For these individuals, insulins that provide the same number of units in a lower injected volume may allow a return to a once-daily regimen. In EDITION 2, a high proportion of those previously on a twice-daily regimen (78%) were using NPH insulin, which has a shorter duration of action than Gla-100; this may have influenced the percentage of participants previously on twice-daily insulin.
The convenience of switching to once-daily dosing may improve quality of life, 1 adherence to therapy, 1 and, consequently, may lead to better glycaemic control. 2 Some people with diabetes, however, may still prefer a twice-daily regimen; this choice should be respected, as effective self-management is reliant on the patient being comfortable with their daily routine. Nevertheless, Gla-300 can be considered as an option for people with T2DM wishing to switch to a once-daily regimen.
Limitations of the present study include its post hoc, exploratory nature. As the EDITION studies were not designed to evaluate the effect of switching from twice-daily to once-daily dosing regimens, this analysis only included a small number of participants. As per the inclusion criteria of the studies, 12,13 participants were receiving relatively high doses of basal insulin, and may not be representative of the global T2DM population; however, this analysis offers clinical evidence on switching from twice-daily to once-daily basal insulin dosing. Further studies investigating switching to Gla-300 in different populations of people with T2DM, including those with lower body mass index and requiring lower doses of insulin, would be of interest.
In conclusion, in this post hoc analysis of 6-month data from EDI-TION 1 and 2, people with T2DM who switched from twice-daily basal insulin to once-daily evening injection of Gla-300 achieved similar glycaemic control with a lower risk of hypoglycaemia compared with those who switched to once-daily Gla-100. These findings suggest that people with T2DM currently on a twice-daily insulin regimen can choose to switch to once-daily Gla-300 while maintaining glycaemic control, without an increased risk of hypoglycaemia.
Switching to once-daily Gla-300 is also likely to reduce the burden of self-management, which may improve adherence and potentially outcomes. 1, 2 As the switching protocol used in the EDITION studies was similar to the guidance now provided in the Gla-300 product label, 16, 17 these findings from the EDITION studies are likely to be relevant to real-life clinical practice. It will be interesting to see whether there are differences observed in glycaemic control between Gla-300 and Gla-100 in "real-life" clinical studies without centrally defined insulin titration algorithms.
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